Aquila Raise $1.75 Million Investment
Aquila Diagnostic Systems Inc. Developing and Commercializing Affordable and Practical Point-of-Care Molecular Diagnostic Testing Solutions
Aquila Diagnostic Systems Inc., an Edmonton–based biotech company with an innovative point-of-care molecular (DNA/RNA) diagnostic solution, announced the closing of a $1.75 million Series A financing round with Benslie International Ltd.
“We are honored to have received financing from Benslie International,” commented Brent James, Aquila’s CEO. “Benslie has made several investments in the medical and biotechnology sectors. They quickly understood the value of our patented hydrogel technology and saw how we can leverage this technology to rapidly develop and deploy point-of-care molecular diagnostic testing solutions on a variety of third-party diagnostic instruments.”